skip to content

Roche’s Hemlibra reduced treated bleeds by 96 percent compared to no prophylaxis in phase III HAVEN 3 study in haemophilia A without factor VIII inhibitors

Media

Media releases
view all

stay updated

get the latest news and updates to your inbox.